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Abstract
Objective: To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian
relapsing-remitting multiple sclerosis (RRMS) population.
Methods: Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisation,
persistence, predictors of treatment discontinuation and switch rates. Multivariable survival analyses were used to compare
treatment persistence between drugs and to identify predictors of treatment discontinuation.
Results: 1113 RRMS patients were studied. Patients persisted on their first disease-modifying therapy (DMT) for a median of
2.5 years. Treatment persistence on GA was shorter than on all IFNb products (p,0.03). Younger age at treatment initiation
and higher EDSS were predictive of DMT discontinuation. Patients persisted on subsequent DMTs, for 2.3 years. Patients
receiving natalizumab (NAT) as a subsequent DMT persisted longer on treatment than those on IFNb or GA (p,0.000). The
primary reason for treatment discontinuation for any drug class was poor tolerability. Annualised switch or cessation rates
were 9.5–12.5% for individual IFNb products, 11.6% for GA and 4.4% for NAT.
Conclusion: This multicentre MS cohort study is the first to directly compare treatment persistence on IFNb and GA to NAT.
We report that treatment persistence in our Australian RRMS population is short, although patients receiving IFNb as a first
DMT persisted longer on treatment than those on GA. Additionally, patients receiving NAT as a subsequent DMT were more
likely to persist on treatment than those switched to IFNb or GA. EDSS and age at DMT initiation were predictive of DMT
discontinuation. Treatment intolerance was the principal reason for treatment cessation.
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Introduction
Multiple Sclerosis (MS) is an inflammatory and degenerative
disease of the central nervous system. For most patients with MS,
the initial disease course features relapses and remissions (RRMS),
whereas the later disease course is characterised by the progressive
accumulation of disability. Early in the course of RRMS,
parenteral disease modifying therapies (DMT), such as interfer-
on-beta (IFNb), glatiramer acetate (GA) or natalizumab (NAT)
reduce the relapse rate and the rate of disability progression
[1,2,3,4].
The concept of treatment adherence encompasses both
compliance and persistence. Compliance can be defined as the
ability to follow a pre-specified administration schedule without
missing doses, which was not assessed in the current study.
Persistence refers to a patient’s ongoing treatment utilisation [5].
Our current understanding of DMT persistence in MS has been
informed by data from a number of sources, including large phase
III trials [6]. However, the environment of a trial does not reflect
typical clinical practice. Many clinical practice-based DMT
utilisation studies have been retrospective or relied on insurance
claims or prescription data [7,8,9]. In general, these studies have
shown poor persistence rates for MS DMTs, but they are
methodologically weakened by bias due to their retrospective
nature and limited clinical data [10,11].
Therefore, we chose to undertake a large, prospective, multi-
centre study of MS therapy utilisation (encompassing persistence),
and predictors of treatment switching and discontinuation. We
sought to assess persistence and switch on all commercially
available DMT including IFNb, GA and NAT all of which have
first-line indications in Australia.
Methods
MSBase Registry
The MSBase Registry (www.msbase.org) is a collaborative
international registry that prospectively collects neurological
outcome data from consenting MS patients attending MS
specialist centres and clinics [12]. The registry is operated by the
not-for-profit MSBase Foundation and its data is physician-owned,
with access freely available to participating neurologists.
Data are collected using an offline, electronic medical record
program called iMed within clinical settings. Quality control of
data is ensured through the use of drop down menus restricting
data entry errors. Data are then anonymised and transmitted to
the MSBase Registry server. The MSBase Registry contains data
collected from over 65 clinics in 28 countries, representing over
20,000 patient datasets. For quality assurance, all participating
neurologists are required to complete online Expanded Disability
Status Scale (EDSS) certification through the Neurostatus online
certification program (www.neurostatus.net).
The Australian MSBase Clinical Cohort
Patients with MS (revised McDonald criteria) were enrolled
from seven Australian academic centres with specialist MS clinics
(The Royal Melbourne Hospital, Vic; Box Hill Hospital, Vic; John
Hunter Hospital, NSW; Brain and Mind Research Institute,
NSW; Flinders Medical Centre, SA; Geelong Hospital, Vic, and
Westmead Hospital, NSW). Patients underwent routine clinical
assessments, were subtyped by clinical course and had the MSBase
minimum dataset updated during routine initial and follow-up
clinic visits [12]. Follow-up visits occurred at least once annually.
Centres provided patients with access to multidisciplinary care,
including nurse education for GA and IFN injection training and
regular follow-up by nurses post initial training.
Data Collection
Treating physicians prospectively collected pre-specified data at
the time of clinic visit.
Treatment start, stop and switch decisions were made in
consultation between patients and their treating physicians during
clinic visits and all treatment identities, start and stop dates were
recorded at that time.
When patients discontinued treatment, a field with categorical
reasons for treatment discontinuation appeared upon entering a
treatment stop date. The reporting of reasons for treatment
discontinuation was not mandated for this analysis, however, all
collected reasons for treatment discontinuation were analysed
(52% of all discontinuations). The captured discontinuation
reasons were balanced across all DMT preparations.
The observation period for this study commenced on 1 January
1998, when MS-specific DMTs became commercially available in
Australia, and ended on the date of data extraction, 10 June 2010.
As MSBase is an ongoing project, data were censored at the
patients’ most recent visit. A minimum of 2 visits per patient were
required to be included in the study; therefore, the observation
interval for each patient was defined by their first and last visits.
Patients with only a single visit recorded were excluded from
analysis. Patients who initiated with their first DMT prior to 1998
were excluded from this study. Only new users were included in
this analysis.
Data extracted from the MSBase Registry on 10 June 2010
comprised 1618 Australian patient datasets, representing approx-
imately 15% of the Australian MS patient population. These
patients were typical of those seen in large tertiary referral centres.
Ethics Statement
All patients gave written informed consent to participate in the
MSBase Registry and Human Research Ethics Committee
(HREC) approval was obtained from all participating centres:
The Royal Melbourne Hospital; Box Hill Hospital; John Hunter
Hospital; Brain and Mind Research Institute; The Southern
Adelaide Clinical HREC; Barwon Health; Western Sydney Local
Health District.
Statistical Analyses
Sex, age, disease course, DMT identity, reasons for treatment
discontinuation, proportion of time treated (PTT) and annualised
switch rates were summarised using frequencies and percentages.
As EDSS, treatment persistence and time to treatment switch all
demonstrated non-normality, these were described using medians
and inter-quartile ranges (IQR). Data assessing treatment duration
were censored at the patients’ most recent clinic visit date. Kaplan-
Meier estimates were used to describe the cumulative probability
of treatment discontinuation. Predictors of treatment discontinu-
ation were analysed using univariable and multivariable Cox
proportional hazards regression and quantified using Hazard
Ratios (HR). Hazard proportionality was assessed by analysis of
scaled Schoenfeld residuals. One-way ANOVA with Bonferroni’s
post hoc test was used to test for differences between continuous
variables, x2 tests were used for categorical variables and Kruskal-
Wallis tests were used to test for differences between discrete
variables.
All reported p values are two-tailed and for each analysis
p,0.05 was considered significant. All analyses were performed
using Stata version 12.0 software package (StataCorp, College
Station, Texas).
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Definitions
PTT was the proportion of time patients were treated with a
DMT as recorded in the MSBase Registry. The PTT assumes
compliance.
Treatment cessation was defined as a break of 90 or more days
with no further DMT use recorded. Patients were considered to
have switched if a subsequent DMT was recorded.
Results
Australian MS Clinical Cohort Demographics
The Australian MSBase Registry cohort had a median follow up
of 2.3 years (IQR: 1.0, 4.4 years). At the date of data extraction,
the average age of the cohort was 45.4 (standard deviation, SD)
12.5 years, comprising 74.4% females and 25.6% males with a
median EDSS of 3 (range 0–9).
The cohort consisted of patients with clinically isolated
syndrome (CIS) 6.0%, RRMS 68.8%, secondary progressive MS
(SPMS) 15.8%, primary progressive MS (PPMS) 6.6% and
progressive relapsing MS (PRMS) 2.8%. For the purposes of the
current study, only RRMS patients were further analysed.
RRMS Patient Demographics
A total of 1113 RRMS patients were followed up for a median
of 2.0 years (IQR 0.80, 4.0). The RRMS population comprised
856 (76.9%) females and 257 (23.1%) males who were predom-
inantly of Caucasian background (95.3%), with the remaining
4.7% comprising Semitic, Asian, Eurasian, Hispanic, African and
Inuit backgrounds. The average age at RRMS diagnosis was 31.8
(SD 10.1) years, with median time to diagnosis of 1.1 years (IQR:
0.33, 3.9 years).
Overview of Treatment Utilisation by RRMS Patients
Median time to treatment initiation with DMTs for patients
diagnosed with RRMS was 0.64 years (IQR 0.16, 3.16) from
clinically definite MS diagnosis date. A total of 724 (65%) RRMS
patients were treated with DMTs at their most recent visit. A total
of 908 (81.6%) patients had used at least one DMT at some point,
while 205 patients (18.4% of the RRMS population) were never
treated with a DMT.
Of the patients treated with a DMT at their most recent visit,
80.4% were treated with either GA or an IFNb preparation,
18.5% were treated with NAT, and 1.8% were treated with
chemotherapeutics.
We recorded 771 first GA/IFNb/NAT treatment commence-
ments. These patients were followed up for a median of 4.2 years
(IQR 2.1, 7.0), and met with their treating physician a median of 6
times (IQR 3, 11) over the observation period. Baseline
characteristics of patients initiating with their first DMT are
summarised in Table 1. Of these 771 first treatment initiations,
only 325 (42.2%) patients were still continuing on their first DMT
at their most recent visit, while 105 (13.6%) patients ceased all
treatments and 43 patients (5.6%) recorded a delayed continuation
(defined as a break from their DMT of 90 days or more only to re-
initiate the same agent). Switch of therapy was recorded in 298
(38.6%) patients.
The median duration off therapy when switching from a first
GA/IFNb therapeutic to a second GA/IFNb/NAT DMT was 28
days (IQR 1, 122), whereas median time off therapy for a delayed
continuation was 452 days (IQR 273, 802).
The female/male ratio for the entire RRMS cohort was 3.3:1.
For patients continuing on treatment, the sex ratio was 3.1:1; for
patients switching treatment it was 3.1:1; for patients disengaging
from treatment the sex ratio was 3.4:1 and for patients who
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recorded a delayed continuation, the sex ratio was 13.3:1 (Pearson
x2, p = 0.08), as the vast majority of these were due to pregnancy.
DMT Persistence
First treatment initiation. Australian RRMS patients
persisted on their first GA/IFNb/NAT DMT for a median
duration of 2.5 years (IQR 1.0, 6.7, n= 771). When analysed by
individual DMT, patients remained on GA for a median of 1.7
years (IQR 0.62, 5.2, n = 117), IFNb-1a IM for a median of 2.6
years (IQR 1.2, 8.5, n= 153), IFNb-1b for a median of 2.8 years
(IQR 1.0, 5.8, n= 270), and IFNb-1a SC for a median of 2.5 years
(IQR 0.70, 7.1, n= 220; Figure 1a). NAT was a rare first choice of
DMT. These patients were followed-up on therapy for an average
of 1.2 years (SD 0.72 years, n = 11). No patients had ceased first-
line NAT treatment at their most recent visit.
Table 2 summarises both univariable and multivariable analyses
of predictors of treatment discontinuation of first recorded DMT.
We found on both unadjusted and adjusted analyses that patients
receiving GA as their first DMT discontinued treatment at a
greater rate than those patients on IFNb-1a IM (HR 1.74,
p = 0.001 on adjusted analysis). Similarly, patients initiating with
GA as their first DMT discontinued treatment at a greater rate
than patients on IFNb-1b (HR 1.47, p = 0.01) or IFNb-1a SC (HR
1.40, p = 0.03, Table S1).
Adjusted, multivariable modelling further revealed that older
age at treatment start (HR 0.79 per 10 years, p,0.000) was an
independent predictor of treatment persistence, and an EDSS of
3.0–5.5 as compared to an EDSS of zero approached significance
as an independent predictor of treatment discontinuation
(Figure 1b). Disease duration at the time of treatment initiation
was shown to predict treatment persistence using univariable
analysis, but it was no longer significant in the adjusted
multivariable analysis. Sex was not predictive of treatment
persistence in this RRMS population (Table 2).
Second and subsequent treatment initiation. Baseline
patient characteristics at initiation of second or subsequent DMT
are summarised in Table 3. Patients persisted on a second or
subsequent GA/IFNb/NAT DMT for a median of 2.3 years (IQR
0.87, 4.9, n = 599). When analysed by individual DMT, patients
remained on GA for a median of 2.0 years (IQR 0.45, 3.9,
n = 172), IFNb-1a IM for a median of 2.5 years (IQR 0.7, 5.1,
n = 102), IFNb-1b for a median of 2.3 years (IQR 0.90, 3.6,
n = 93), and IFNb-1a SC for a median of 1.6 years (IQR 0.67, 4.8,
n = 101). Patients were followed-up on NAT for an average of 1.2
years (SD 0.67 years, n = 131). NAT discontinuation events were
rare (n = 18). Adjusted Cox proportional hazards regression
revealed that the hazard ratio for treatment discontinuation was
0.26 (p,0.000; Table 4 and Figure 2a) if using NAT as compared
to IFNb-1a IM. Similarly, the hazard ratio for treatment
discontinuation was significantly smaller (p,0.000) for NAT as
compared to IFNb-1b, IFNb-1a SC and GA (see Table S2). There
were no differences in treatment persistence between IFNb
preparations or GA when used as a second or subsequent DMT.
Adjusted multivariable analyses revealed that older age at
treatment start was again predictive of treatment persistence (HR
0.85 per 10 years, p = 0.017). Additionally, EDSS at treatment
start was independently predictive of treatment discontinuation on
a subsequent DMT. EDSS 1–2.5 (HR 1.98, p= 0.046), EDSS 3–
5.5 (HR 2.40, p = 0.013), and EDSS 6+ (HR 2.90, p= 0.008) were
associated with greater rates of discontinuation relative to an
EDSS of 0 (Table 4 and Figure 2b). Disease duration at treatment
start and sex were not predictive of treatment discontinuation on a
second or subsequent DMT (Table 4).
Treatment Discontinuation
While the recording of reasons for treatment discontinuation
does not constitute part of the MSBase minimum dataset,
categorical reasons were collected for approximately 52% of all
discontinuations (see Table 5). Reasons included: lack of
tolerance/adverse event, convenience, lack of improvement,
progression of disease and scheduled stop. Here we report that
by far the most common reason for treatment discontinuation was
lack of tolerance/adverse event (42.9%–64.7% of all responses).
There were no statistically significant differences between DMTs
for any categorical discontinuation descriptors (Table 5).
Proportion of Time Treated, Treatment Cessations and
Switches
Annualised PTT was calculated for all DMTs based on
treatment commencements and cessations between 11 June 2008
Figure 1. Kaplan-Meier survival estimates for treatment discontinuation (First DMT). A: Treatment discontinuation by DMT. This figure
demonstrates that patients prescribed Glatiramer Acetate as a first DMT discontinue treatment at a significantly greater rate than those prescribed
any of the IFNb preparations (adjusted Cox Proportional Hazards Regression, p,0.03). B: Treatment discontinuation by EDSS. This figure
demonstrates that patients with an EDSS of 3–5.5 discontinue the use of a first DMT at a greater rate than those with an EDSS of 0 (adjusted Cox
Proportional Hazards Regression, p = 0.08).
doi:10.1371/journal.pone.0059694.g001
Australian Multiple Sclerosis Immunotherapy Study
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to 10 June 2010, the date of data extract. There were 535 patients
who were treated with DMT during this observation period, with
a median annualised PTT of 0.87 (IQR 0.47, 1).
Annualised treatment switch rates were calculated based on
treatment commencements and cessations for each individual drug
over the same two-year period as above. The annualised treatment
switch rates for these DMTs were as follows: IFN-1a IM, 9.5% per
annum; IFN-1b, 12.5% per annum; GA, 11.6% per annum; IFN-
1a SC, 10.0% per annum and NAT 4.4% per annum.
Concerning switches within the interferon class, there was no
evidence to suggest preferential switching (Table 6). Patients
switching from IFNb preparations switched to another interferon
class (44.4%), to GA (36.6%) or to NAT (19.0%). The majority of
patients switching from GA changed to an IFNb preparation
(73.7%) while just over a quarter of patients treated with GA
Table 2. Predictors of first treatment discontinuation.
Predictor Level
Discontinuations
n=460
Unadjusteda HR (95% CI)
p-value Adjusteda# HR (95% CI) p-value
Demographics
Sex Female 359 1.00 1.00
Male 101 1.02 (0.82, 1.27) 0.883 0.99 (0.79, 1.24) 0.935
Disease duration at treatment start per 10 years 2 0.84 (0.72, 0.98) 0.029 0.96 (0.81, 1.14) 0.670
Age at treatment start per 10 years 2 0.81 (0.74, 0.89) 0.000 0.79 (0.71, 0.87) 0.000
Treatment
IFNb-1a IM 83 1.00 1.00
IFNb-1b 179 1.28 (0.99, 1.67) 0.061 1.19 (0.91, 1.55) 0.199
IFNb-1a SC 133 1.33 (1.01, 1.76) 0.042 1.24 (0.94, 1.65) 0.130
GA 65 1.75 (1.26, 2.43) 0.001 1.74 (1.25, 2.42) 0.001
EDSS
EDSS (categorical) at treatment start 0 40 1.00 1.00
1–2.5 91 0.89 (0.61, 1.28) 0.522 0.98 (0.67, 1.43) 0.913
3–5.5 57 1.19 (0.80, 1.79) 0.390 1.45 (0.96, 2.20) 0.078
$6 7 0.92 (0.41, 2.04) 0.829 1.16 (0.51, 2.66) 0.717
missing* 265 0.70 (0.50, 0.98) 0.036 0.78 (0.56, 1.10) 0.163
Abbreviations: n: number, HR: Hazard Ratio, CI: Confidence Interval, IFN: Interferon, IM: intramuscular, SC: Subcutaneous, GA: Glatiramer Acetate, EDSS: Expanded
Disability Status Scale.
Treatment initiations n = 760 excluding Natalizumab (n = 11).
aCox Proportional Hazards Regression.
Multivariable Cox Proportional Hazards model was adjusted for sex, disease duration, age at treatment start, treatment and EDSS.
# Proportional hazards test: p = 0.3747.
*No EDSS score available at the time of treatment start.
doi:10.1371/journal.pone.0059694.t002
Figure 2. Kaplan-Meier survival estimates for treatment discontinuation (Subsequent DMT). A: Treatment discontinuation by DMT. This
figure demonstrates that patients prescribed Natalizumab as a subsequent DMT discontinue treatment at a significantly slower rate than those
prescribed Glatiramer Acetate or any of the IFNb preparations (adjusted Cox Proportional Hazards Regression, p = 0.000). B: Treatment
discontinuation by EDSS. This figure demonstrates that patients with EDSS 1–2.5 (p = 0.046), EDSS 3–5.5 (p = 0.013) and EDSS $6 (p = 0.008)
discontinue treatment at a significantly greater rate than those with EDSS 0 (adjusted Cox Proportional Hazards Regression).
doi:10.1371/journal.pone.0059694.g002
Australian Multiple Sclerosis Immunotherapy Study
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initially changed to NAT (26.3%). At the time of data extraction,
no patients for whom NAT was their first-recorded DMT (n= 11)
had switched treatment.
Discussion
Poor adherence to long term therapies in a chronic disease such
as MS is thought to be a major contributor to the health care
burden and, conversely, improved adherence to extant therapies is
postulated to potentially have a greater impact on health outcomes
than the development of new therapeutics [13].
Use of disease modifying therapies in MS has been shown in
randomised controlled trials (RCT) to decrease relapse rate and
disability progression [3,4,14,15]. In a global survey commissioned
by the World Health Organisation, it was reported that the
median percentage of patients in high income countries receiving
DMT is 75% [16]. Concordant with this report, in our study we
show that 65% of eligible patients in our registry were treated at
the time of data extraction and that in the most recent two-year
observation period, our patients prescribed DMT spent 87% of
this time on treatment. However, we also found that 18.4% of
RRMS patients had never engaged with treatment. The propor-
tion of RRMS patients not engaging with treatment likely
represents a heterogeneous group comprising some with relatively
mild disease, and others choosing not to engage with parentally
administered treatments. With the recent approval by the
Therapeutics Goods Administration of the oral therapeutic
fingolimod in Australia from September 2011, and with other
oral therapeutics in the pipeline, it will be interesting to determine
whether the proportion of RRMS patients engaging with DMT
will increase in the future.
This is the first large-scale, multicentre, prospective study of MS
treatment utilisation in Australia. The Australian health care
system, through the Pharmaceutical Benefits Scheme, provides
drug cost coverage for RRMS patients for all IFNb preparations,
GA and NAT, removing confounding issues of drug cost and
insurance coverage from the current analysis. Most previous
studies of treatment persistence in MS have used retrospective
administrative claims data [7,8,9,17]. In comparison, a key
strength of our study is its prospective nature. Outcomes data
are recorded at the time of the clinical encounter into an electronic
medical record by MS clinicians, eliminating recall bias,
transcriptional errors and avoiding duplicate records. However,
this study comprises datasets of patients seen at academic centres
who have volunteered to participate in the MSBase Registry,
therefore this study is subject to selection bias.
In Australia, GA, IFNb and NAT all have first-line indications
with no differences in criteria for use, therefore switch decisions
were at the discretion of the treating physician and their patient. In
the current study, treatment persistence on immunotherapy was
relatively short and therapy switches were common. We report a
median duration of only 2.6 years on a first DMT and 2.3 years on
a subsequent DMT. Interestingly, product identity was associated
with different treatment discontinuation rates where patients
receiving NAT as a subsequent DMT were more likely to persist
on treatment as compared to those on IFNb or GA; and patients
receiving GA as their first DMT were more likely to cease
treatment than patients on IFNb-1a IM. These prospective data
are concordant with that reported by Kleinman et al [8] who
found, using retrospective US healthcare claims data, that IFNb
preparations were associated with a lower discontinuation rate
than GA. However, this finding is to some extent in contrast to the
adherence outcome of our previous global study [18] and the
REGARD study [19]. In the REGARD study, the overall
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persistence rate for GA and IFNb-1a SC over 96 weeks was
similar, at around 80%. This discrepancy also highlights a major
difference in persistence rates reported in clinical trials, such as
REGARD, compared to reports from country-specific clinical
practice studies, such as the present study or the recently published
Ontario data [20], which report persistence rates of less than 50%
at three years and two years post DMT initiation.
Treatment adherence and persistence rates are known to be
influenced by country of residence [9,21,22] with higher
adherence rates reported in Italy and Spain compared to Canada
and Australia. Common comorbidities such as depression also
influence persistence [23]. In a global analysis of DMT utilisation
in CIS and early RRMS in the MSBase registry [18], females were
more likely to discontinue than males. This was not replicated in
Table 4. Predictors of subsequent treatment discontinuation.
Predictor Level
Discontinuations
n=296
Unadjusteda HR (95% CI) p-
value
Adjusteda# HR (95% CI) p-
value
Demographics
Sex Female 241 1.00 1.00
Male 55 1.02 (0.76, 1.36) 0.920 1.11 (0.82, 1.49) 0.512
Disease duration at treatment start per 10 years 2 1.03 (0.87, 1.23) 0.742 1.10 (0.90, 1.33) 0.345
Age at treatment start per 10 years 2 0.93 (0.83, 1.04) 0.205 0.85 (0.75, 0.97) 0.017
DMT
Therapeutic IFNb-1a IM 56 1.00 1.00
IFNb-1b 59 1.18 (0.82, 1.71) 0.356 1.09 (0.75, 1.58) 0.657
IFNb-1a SC 66 1.18 (0.83, 1.69) 0.354 1.10 (0.77, 1.57) 0.611
GA 97 1.29 (0.93, 1.79) 0.133 1.25 (0.90, 1.74) 0.190
NAT 18 0.37 (0.21, 0.63) 0.000 0.26 (0.15, 0.45) 0.000
EDSS
EDSS (categorical) at treatment start 0 10 1.00 1.00
1–2.5 67 1.65 (0.85, 3.21) 0.139 1.98 (1.01, 3.86) 0.046
3–5.5 61 1.54 (0.79, 3.02) 0.203 2.40 (1.20, 4.81) 0.013
$6 18 1.98 (0.91, 4.28) 0.084 2.90 (1.31, 6.42) 0.008
missing* 140 1.32 (0.69, 2.52) 0.403 1.34 (0.70, 2.58) 0.379
Abbreviations: n: number, HR: Hazard Ratio, CI: Confidence Interval, IFN: Interferon, IM: intramuscular, SC: Subcutaneous, GA: Glatiramer Acetate, NAT: Natalizumab,
EDSS: Expanded disability status scale.
Treatment initiations n = 599.
aCox Proportional Hazards Regression.
Multivariable Cox Proportional Hazards model was adjusted for sex, disease duration, age at treatment start, treatment and EDSS.
# Proportional hazards test: p = 0.2270.
*No EDSS score available at treatment start.
doi:10.1371/journal.pone.0059694.t004
Table 5. Categorical reasons for treatment discontinuation for all treatment commencements.
IFNb-1a IM IFNb-1b IFNb-1a SC GA NAT
p-value Between
treatment groups
No. of Commencements – n 465 702 499 529 243
No. of Discontinuations – n 276 474 307 286 56
No. of Recorded Reasons for
Discontinuation – n (%)
128 (46.4) 228 (48.1) 150 (48.9) 155 (54.2) 35 (62.5)
Reasons Recorded – n (%)
Adverse Event/Lack of Tolerance 66 (51.6) 125 (54.8) 97 (64.7) 95 (61.3) 15 (42.9) 0.345a
Convenience 5 (3.9) 17 (7.5) 6 (4.0) 9 (5.8) 6 (17.1) 0.035a
Lack of Improvement 16 (12.5) 24 (10.5) 18 (12.0) 20 (12.9) 4 (11.4) 0.447a
Progression of Disease 23 (18.0) 34 (14.9) 16 (10.7) 22 (14.2) 7 (20.0) 0.382a
Scheduled Stop 18 (14.0) 28 (12.3) 13 (8.6) 9 (5.8) 3 (8.6) 0.061a
Total 128 (100) 228 (100) 150 (100) 155 (100) 35 (100)
Abbreviations: n, number.
aPearson x2 test.
doi:10.1371/journal.pone.0059694.t005
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our Australian cohort, with males and females being equally likely
to cease first DMT. Consistent with previous registry studies, we
report that patients with a higher EDSS were more likely to
discontinue treatment [18,21,22]. Additionally, we found that
older patients were more likely to persist on therapy than younger
patients independent of treatment identity or order.
The reasons for DMT discontinuation are rarely identified in
the persistence literature, but three studies report poor tolerability,
perceived lack of efficacy and adverse events as reasons for
discontinuation [9,21,22]. Concordant with these results, by far
the most common reason for DMT discontinuation in our study
was lack of treatment tolerance or treatment-related adverse event.
A limitation of the current study is the incomplete capture of
causes for treatment discontinuations (52% of all discontinuations
were assigned a reason). However, the data available are evenly
distributed across all the therapies and therefore likely to be
representative of causes for treatment cessation. Additionally,
whilst compliance was encouraged in our centres through the
provision of immunotherapy training and regular nurse follow-up
post-injection training, we were not able to ascertain compliance
in this study.
In summary, in this prospective multicentre study, we have
demonstrated that in Australian tertiary centres with specialist MS
care clinics, median treatment persistence is relatively short; 2.5
years first initiation, 2.3 years subsequent initiation. We report that
older age at treatment initiation is associated with greater
treatment persistence and that higher EDSS is independently
predictive of treatment discontinuation. We further report that
treatment persistence was poorest on GA as a first DMT, however,
there were no differences in treatment persistence between GA or
any of the IFNb preparations as subsequent therapies. Treatment
persistence was greatest for NAT. The most common reason for
treatment discontinuation is poor treatment tolerability. Overall,
this clinical practice-based study highlights the significant unmet
need to develop effective MS therapies with improved tolerability,
and to implement country-specific strategies that enhance
medication persistence in this chronic, life-long condition.
Supporting Information
Table S1 Predictors of first treatment discontinuation.
Table reports univariable and multivariable Cox proportional
hazards regression analysis. Comparator group: GA-treated
patients.
(DOCX)
Table S2 Predictors of subsequent treatment discontin-
uation. Table reports univariable and multivariable Cox
proportional hazards regression analysis. Comparator group:
NAT-treated patients.
(DOCX)
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